Clinical Trial Search

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants

Primary: Part 1 and Part 2: Number of Participants With Adverse Events — 3; 4; 5; 274 Participants

Primary: Overall Response Rate — 40; 55; 29 percentage of patients

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Objective Response Rate — .85 proportion of patients

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation — 3; 9; 5; 19 Participants

Primary: Progression-free Survival at 2 Years — 15 Participants

Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…

Primary: Overall Response Rate — 81.8 Percentage

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants

Primary: Total Number of Adverse Events. — 2 Adverse events

Primary: Optimal Biologic Dose of MEDI-551 for Part A — 12 mg/Kg

Primary: ORR — 88; 81 percentage of patients

Primary: Number of Participants (Par.) During Initial Treatment Exposed to the Indicated Dose Levels of the Therapeutic Dose (TD), Re-dose, and Total Dose (TD + Re-dose) — 6; 1…

Primary: Percentage of Participants With Complete Response (CR) at End of Treatment Period — 31; 25 percentage of participants

Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants

Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants

Primary: Rate of Successful Manufacture of CD22 CAR T Cells — 94; 100; 100 Percentage

Primary: Overall Response Rate (Complete Response and Partial Response) After Three Inductions Cycles of Treatment. — 71 percentage of patients

Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 21; 8 participants

Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants

Primary: Part 1 : Number Of Participants Experiencing Adverse Events — 12; 7 Participants

Primary: Number of Participants With Toxicity — 8 participants

Primary: Overall Response — 3; 3; 3; 2 Participants

Primary: Progression Free Survival — 389; 334 days — p=0.039